BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10402244)

  • 1. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
    Toma S; Ugolini D; Palumbo R
    Int J Oncol; 1999 Aug; 15(2):321-37. PubMed ID: 10402244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis.
    Beguerie JR; Xingzhong J; Valdez RP
    Int J Dermatol; 2010 Oct; 49(10):1194-202. PubMed ID: 20883410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
    McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
    Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for metastatic melanoma.
    Mandarà M; Nortilli R; Sava T; Cetto GL
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):121-30. PubMed ID: 16375649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemohormonal therapy for malignant melanomas of the nasal and paranasal mucosa.
    Seo W; Ogasawara H; Sakagami M
    Rhinology; 1997 Mar; 35(1):19-21. PubMed ID: 9200258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast cancer].
    Hoeller U; Borgmann K; Feyer P; Souchon R;
    Strahlenther Onkol; 2007 Oct; 183(10):535-44. PubMed ID: 17896084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
    McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
    Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinology of melanoma.
    Neifeld JP
    Semin Surg Oncol; 1996; 12(6):402-6. PubMed ID: 8914204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta 1-induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen.
    Müllauer L; Grasl-Kraupp B; Bursch W; Schulte-Hermann R
    Hepatology; 1996 Apr; 23(4):840-7. PubMed ID: 8666340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma.
    Gelmann EP
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-65-S1-70. PubMed ID: 9045318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of cisplatin resistance in human malignant melanoma cells.
    McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
    Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
    McClay EF; McClay ME
    J Clin Oncol; 1994 Mar; 12(3):617-26. PubMed ID: 8120562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.